Agios Pharmaceuticals stock
AGIONASDAQAgios Pharmaceuticals, Inc., HealthcareISIN US00847X1046
40Score 40 out of 100, Weak
Price and trend
58 / 100
Price history
−27% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.2% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 30% below its 52-week high. Largest decline in 13 years: 87% (January 2015 to June 2022).
Chart figures for advanced users
- SMA 50$33.12
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.34
- The lowest closing price of the last twelve months.
- Resistance$45.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Agios Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.9B, is number 134 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $54.03M (up 48% year on year) and a loss of $412.78M.
- For fiscal 2026, analysts expect on average revenue of $176.72M (up 227.1%) and adjusted earnings per share of −$5.77.
Show more
- MEQIRI Score 40 out of 100 (Weak): rank 550 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $630.01M, financial debt $26.53M.Stability 70
- Share buybacksShare count down 16% since 2020.
Weaknesses
- Loss-makingLoss of $372.9M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$335.97M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 80% a year over the last 12 months.
Its standout strength is stability, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 40.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 48% on the prior year. Revenue has grown strongly since 2022, at around 56% per year. From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating −874%, net −764%. Last 12 months: net −100%. From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 5 Nov 2026EPS reported −$1.09 (expected −$1.24)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$5.77−0.5%
- Revenue
- $176.72M−0.7%
- Earnings per share
- −$3.75−0.2%
- Revenue
- $347.42M+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −14.3%Guidance maintained: still about $45 million to $50 million of US PK deficiency revenue, operating expenses roughly flat versus 2025.
“We continue to expect approximately $45 million to $50 million from PK deficiency revenues in the U.S.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.44M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Agios Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- First Tracks BiotherapeuticsTRAX $2.12B47
- ZymeworksZYME $2.02B63
- Harmony Biosciences HoldingsHRMY $2.01B73
- BioCryst PharmaceuticalsBCRX $1.97B37
- Zenas BioPharmaZBIO $1.95B38
- Fortrea HoldingsFTRE $1.93B41
- Kailera TherapeuticsKLRA $1.87B41
- Hemab Therapeutics HoldingsCOAG $1.84B47
ETFs that hold Agios Pharmaceuticals
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.35% | 0.49% | €26.29M |
| iShares Ageing Population UCITS ETF2B77 | 0.16% | 0.40% | €807M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.11% | 0.35% | €1.21B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.